These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37314151)

  • 1. Antiviral treatment or mAbs for persistent SARS-COV-2 infection in patients with hematologic malignancies: A case series.
    Pérez-Catalán I; Gómez-Alfaro I; García-Muñoz S; Roig-Martí C; Rodríguez-Lozano N; Fabra-Juana S; Esteve-Gimeno MJ; Gascón-Buj A; Freiria-Alberte C; Clavel-Pia J; Torres-García M; Reig-Valero R; Ferrando-Piqueres R; Mateu-Campos L; Usó-Blasco J; Ramos-Rincón JM
    J Med Virol; 2023 Jun; 95(6):e28865. PubMed ID: 37314151
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review.
    SeyedAlinaghi S; Karimi A; Mirzapour P; Salmani R; Razi A; Mojdeganlou H; Mojdeganlou P; Qodrati M; Jashaninejad R; Paranjkhoo P; Dadras O; Zarezadeh B; Afsahi AM; Afzalian A; Varshochi S; Mehraeen E; Afsahi G
    Infect Disord Drug Targets; 2023; 23(7):29-38. PubMed ID: 37138433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.
    Laracy JC; Kamboj M; Vardhana SA
    Curr Opin Infect Dis; 2022 Aug; 35(4):271-279. PubMed ID: 35849516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
    Wang L; Wang W; Xu R; Berger NA
    Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 in patients with hematologic malignancy.
    Langerbeins P; Hallek M
    Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
    Haggenburg S; Hofsink Q; Rutten CE; Nijhof IS; Hazenberg MD; Goorhuis A
    Semin Hematol; 2022 Oct; 59(4):192-197. PubMed ID: 36805887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.
    Niu A; Ning B; Socola F; Safah H; Reynolds T; Ibrahim M; Safa F; Alfonso T; Luk A; Mushatt DM; Hu T; Saba NS
    Leuk Res; 2021 Jul; 106():106582. PubMed ID: 33933714
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
    Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
    J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 infection and mortality in pediatric patients with hematological malignancies and solid tumors.
    Aguiar JEAT; Carvalho MAL; Viana SS; Martins-Filho PR; Cipolotti R
    Pediatr Hematol Oncol; 2023 May; 40(4):429-432. PubMed ID: 36094799
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
    Mikulska M; Testi D; Russo C; Balletto E; Sepulcri C; Bussini L; Dentone C; Magne F; Policarpo S; Campoli C; Miselli F; Cilli A; Ghiggi C; Aquino S; Di Grazia C; Giannella M; Giacobbe DR; Vena A; Raiola AM; Bonifazi F; Zinzani P; Cavo M; Lemoli R; Angelucci E; Viale P; Bassetti M; Bartoletti M
    Br J Haematol; 2023 May; 201(4):628-639. PubMed ID: 36806152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SARS-COV-2 infection in patients with hematological malignancies and transplants].
    Herrera F; Bues F; Rojas R; Temporiti E; Videla C; Dupont J; Bonvehí P
    Medicina (B Aires); 2021; 81(3):396-400. PubMed ID: 34137699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.
    Garcia-Vidal C; Puerta-Alcalde P; Mateu A; Cuesta-Chasco G; Meira F; Lopera C; Monzo P; Santos-Bravo M; Duenas G; Chumbita M; Garcia-Pouton N; Gaya A; Bodro M; Herrera S; Mosquera M; Fernandez-Aviles F; Martinez JA; Mensa J; Gine E; Marcos MA; Soriano A
    Haematologica; 2022 Jul; 107(7):1731-1735. PubMed ID: 35295080
    [No Abstract]   [Full Text] [Related]  

  • 17. Central venous catheter-related bloodstream infections in patients with haematological malignancies during the SARS-CoV-2 pandemic.
    Schalk E; Schmitt T; Panse J; Fiegle E; Naendrup JH; Schmidt-Hieber M; Böll B; Hentrich M; Teschner D; Mougiakakos D
    Br J Haematol; 2022 Nov; 199(4):e16-e20. PubMed ID: 36017820
    [No Abstract]   [Full Text] [Related]  

  • 18. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.
    Ni B; Yanis A; Dee K; Chappell JD; Dulek DE; Kassim AA; Kitko CL; Thomas LD; Halasa N
    Blood Rev; 2022 Nov; 56():100984. PubMed ID: 35752546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
    El Chaer F; Auletta JJ; Chemaly RF
    Blood; 2022 Aug; 140(7):673-684. PubMed ID: 35776899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.
    Glenthøj A; Jakobsen LH; Bjørn ME; Poulsen CB; Sengeløv H; Severinsen MT; Qvist K; Overgaard UM; Ahmad SA; Rewes A; Mølle I; Strandholdt CN; Kodahl AR; Ryg J; Brieghel C; Johansen IS; Kannik K; Jensen-Fangel S; Wiese L; Kirk O; Clausen MR; Helleberg M; Frederiksen H
    Acta Oncol; 2022 Apr; 61(4):500-504. PubMed ID: 35038967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.